



Glaukos Technologies Featured in Numerous Presentations at 2016 American Society of Cataract and Refractive Surgery

2016-04-28

Surgeons to Present Recent Personal Experience Data and Clinical Results at Annual American Medical Conference

NEW ORLEANS--(BUSINESS WIRE)-- [Glaukos Corporation](#) (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in numerous presentations at the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting being held at the Ernest N. Morial Convention Center in New Orleans, LA on May 6-10, 2016.

"The ASCRS provides a solid line-up of surgeon presentations that showcase clinical results of our flagship *iStent® Trabecular Micro-Bypass Stent* and next-generation micro-scale glaucoma devices designed to provide sustained reduction in intraocular pressure," said Thomas Burns, Glaukos president and chief executive officer. "This growing body of clinical evidence supports our goal to transform the glaucoma treatment algorithm with a comprehensive set of micro-scale therapies that surgeons can use serially or in combination to manage patients' intraocular pressure across the full spectrum of glaucoma disease states and progression."

Key Presentation Topics by Day and Time (Central Daylight Time):

Saturday, May 7, 2016

1. Richard Lindstrom, MD: Use of Second Generation Trabecular Stents as Sole Procedure in Eyes with Open-Angle Glaucoma on 1 Preoperative Medication: 18-Month Report

Paper Session 1-F: GLAUCOMA: MIGS, 1:25-1:30 p.m., Room 224

2. Jonathan Davidort, MD: Trabecular Microbypass Stent in Clinical Practice

Paper Session 1-F: GLAUCOMA: MIGS, 1:35-1:40 p.m., Room 224

3. Steven Vold, MD: Management of IOP Through 3 Years with 2 Ab Interno Trabecular Stents or Prostaglandin in Newly Diagnosed OAG: Prospective Randomized Study

Paper Session 1-F: GLAUCOMA: MIGS, 1:48-1:53 p.m., Room 224

4. Mark Gallardo, MD: Intraocular Pressure Control with Reduced Medication Burden After Cataract Surgery and Ab Interno Trabecular Stent Implantation for OAG and Cataract

Paper Session 1-F: GLAUCOMA: MIGS, 1:53-1:58 p.m., Room 224

5. L. Jay Katz, MD: Medication and IOP Decrease Through 30 Months in OAG Patients on Preoperative Medication Randomized to 1, 2, or 3 Trabecular Bypass Stents as Sole Surgery

Paper Session 1-F: GLAUCOMA: MIGS, 2:03-2:08 p.m., Room 224

6. Tanner Ferguson: Evaluation of a Trabecular Microbypass Stent in Combination with Endocyclophotocoagulation in Patients with Glaucoma and Cataract

Paper Session 1-F: GLAUCOMA: MIGS, 2:08-2:13 p.m., Room 224

7. Michael Stiles, MD: Trabecular Bypass Stent and Cataract Surgery in Glaucoma Patients with Previous Medical/Surgical Therapy: 2-Year Single-Site Outcomes

Paper Session 1-K GLAUCOMA: MIGS/Canaloplasty, 3:12-3:17 p.m., Room 223

8. John Berdahl, MD: Microinvasive Glaucoma Surgery with Second-Generation Trabecular Stents and Postoperative Prostaglandin to Treat OAG Patients on 2 Preoperative Medications

Paper Session 1-K GLAUCOMA: MIGS/Canaloplasty, 3:22-3:27 p.m., Room 223

9. John Berdahl, MD; Tanner Ferguson; Ramu Sudhagoni, PhD: Evaluation of a Trabecular Microbypass Stent with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataract

Paper Session 1-K GLAUCOMA: MIGS/Canaloplasty, 3:27-3:32 p.m., Room 223

Sunday, May 8, 2016

10. Carlos Buznego, MD: Long-Term Results of Trabecular Microbypass Stent at a Single Site

Paper Session 2-R: GLAUCOMA: MIGS, Trabulectomy, 3:26-3:31 p.m., Room 224

11. Reay Brown, MD: Intraocular Pressure Reduction After Cataract Surgery with a Trabecular Microbypass Device: Longer-Term Follow-up

Paper Session 2-R: GLAUCOMA: MIGS, Trabulectomy, 3:31-3:36 p.m., Room 224

EyeWorld/ASCRS Authorized Education (Central Daylight Time):

Sunday, May 8, 2016

MIGS Devices: NewData, Outcomes and Surgical Pearls for the Comprehensive Surgeon

Registration & Reception: 4:45-5:15 p.m.
Program: 5:15-6:15 p.m.
Marriott Convention Center, Blaine Kern Ballroom

Moderator: John Hovanesian, MD
Faculty: John Berdahl, MD
David Chang, MD
Richard Lewis, MD
Cathleen McCabe, MD
Inder Paul Singh, MD

The annual ASCRS meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. Glaukos will be exhibiting at booth #1929 on the showroom floor.

Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS), which involves the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. The MIGS device reduces intraocular pressure by restoring the natural outflow pathways for aqueous humor. In 2012, Glaukos received U.S. Food & Drug Administration (FDA) approval and launched its first MIGS device, the *iStent*, which has been shown to lower intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma undergoing cataract surgery. The company is also pursuing FDA approval for three additional micro-scale glaucoma therapies, including:

- The *iStent inject*[®] *Trabecular Micro-Bypass Stent*, which includes two stents preloaded in an auto-injection mechanism that allows an ophthalmic surgeon to inject stents into multiple trabecular meshwork locations through a single corneal entry point. The company has U.S. IDE clinical trials underway for two versions of the *iStent inject*, one for use in conjunction with cataract surgery and another for use in a standalone procedure. The *iStent inject* has been approved in the European Union, Australia and Canada.
- The *iStent SUPRA*[®] *Suprachoroidal Micro-Bypass Stent*, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye. A U.S. IDE clinical trial is underway for the *iStent SUPRA*, which is approved in the European Union.
- The *Travoprost Intraocular Implant with iDose*[™] *Delivery System*, which is designed to be injected through a clear corneal incision and secured in the anterior chamber where it continuously elutes therapeutic levels of a prostaglandin medication from within the eye for extended periods of time. A Phase II U.S. IND trial for the *iDose* began in 2016.

About *iStent*[®] *Trabecular Micro-Bypass*

Indication for Use: *The iStent Trabecular Micro-Bypass Stent* is indicated for use in conjunction with

cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate open-angle glaucoma currently treated with ocular hypotensive medication.

Contraindications: The *iStent* is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings: Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The *iStent*[®] is MR-Conditional, meaning that the device is safe for use in a specified MR environment under specified conditions; please see label for details.

Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the *iStent*[®] has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after “washout” of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.

Adverse Events: The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of = 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.

Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.

About Glaukos Corporation

Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the *iStent*[®], its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the *iStent*, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA. (www.glaukos.com)

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address

activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties include, without limitation, our ability to secure regulatory approval for our next-generation products and technologies and the efficacy of our current and future products. These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K for the year ended December 31, 2015, which we filed with the Securities and Exchange Commission on March 14, 2016. Our filings with the Securities and Exchange Commission are available in the Investor section of our website at www.glaukos.com or at www.sec.gov. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

View source version on
businesswire.com: <http://www.businesswire.com/news/home/20160428005446/en/>

Source: Glaukos Corporation

for Glaukos Corporation

Media Contact:

Cassandra Dump, 619-971-1887

Cassy@pascalecommunications.com

or

Investor Contact:

Sheree Aronson, 949-367-9600 Ext. 371

saronson@glaukos.com